Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase
Status:
Terminated
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase is to evaluate the long-term safety and tolerability of BTDS.
Qualified subjects are started on BTDS 5 and the dose may be titrated, if necessary, to a
maximum of BTDS 20 to achieve stable pain control.